LifeStance Health Group, Inc. LFST R2K

Healthcare · Medical Care Facilities · United States

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Market & Price

Market Cap

$2.94B

Current Price

$7.71

High / Low (52W)

$8.85 / $3.79

Beta

1.20

Valuation

Stock P/E

128.50

Industry PE

23.65

Forward P/E

19.51

PEG Ratio

Book Value

$3.81

Price to Book

2.02

P/S

1.97

EV/EBITDA

32.64

Dividend Yield

Profitability & Returns

ROCE

1.23%

ROE

1.58%

ROA

1.35%

Profit Margin

1.55%

Op Margin

5.54%

EPS (Latest Qtr)

$0.04

EPS (TTM)

$0.06

Balance Sheet & Liquidity

Debt/Equity

0.32

Quick Ratio

1.32

Current Ratio

1.49

Debt

$476.77M

Total Assets

$2.20B

Current Assets

$416.20M

Working Capital

$164.24M

Ownership

Promoter Holding

4.59%

Chg in Prom Hold

FII / Inst Holding

88.56%

Chg in FII Hold

0.02%

Financial Snapshot

Enterprise Value

$3.27B

Total Revenue (TTM)

$1.49B

EBITDA

$100.25M

Free Cash Flow

$140.70M

Operating Cash Flow

$182.35M

Shares Outstanding

381.83M

Gross Margin

32.60%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

18.33%

Profit 5Y

34.83%

Revenue (YoY)

21.20%

Earnings (YoY)

1,927.50%

PROS

Compounding revenue at 18.3% over 5 years.
Profit CAGR of 34.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 128.5.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	LFST LifeStance Health Group, Inc. R2K	7.71	128.50	$2.94B	-	1.23%	1.58%	18.33%	34.83%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	16.00K	44.00K	-	1.36M	-	-	-	-	-	-	-	-	-	-	332.97M	345.31M	363.81M	382.19M	403.48M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	223.18M	236.88M	247.23M	255.90M	267.54M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109.79M	108.43M	116.58M	126.30M	135.93M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	108.19M	111.38M	109.17M	108.21M	113.65M
Operating Income	104.00K	2.69M	-881.00K	-47.05M	-124.67M	-64.85M	-60.47M	-38.84M	-34.09M	-48.41M	-74.36M	-16.77M	-15.95M	-	1.60M	-2.95M	7.41M	18.08M	22.28M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.36M	10.96M	20.94M	31.51M	34.87M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.07M	2.90M	2.81M	2.88M	1.79M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.47M	-5.94M	4.57M	15.20M	19.76M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.18M	-2.15M	3.50M	3.54M	5.52M
Net Income	-4.34M	-3.29M	-8.68M	-70.03M	-120.45M	-62.33M	-68.73M	-37.85M	-34.24M	-45.48M	-61.58M	-21.10M	-23.28M	-	709.00K	-3.79M	1.08M	11.67M	14.24M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.02	0.00	-0.01	0.00	-	0.04

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	859.54M	1.06B	1.25B	1.42B
Cost of Revenue	-	-	622.52M	753.57M	848.57M	963.19M
Gross Profit	-	-	237.02M	302.10M	402.40M	461.10M
Operating Expenses	-	-	447.19M	491.23M	434.01M	436.95M
Operating Income	15.24M	-	-210.17M	-189.13M	-31.61M	24.15M
EBITDA	-	-	-143.60M	-104.93M	39.87M	78.78M
Interest Expense	-	-	19.93M	21.22M	26.54M	11.66M
Pretax Income	-	-	-232.73M	-206.58M	-57.61M	12.36M
Tax Provision	-	-	-17.17M	-20.32M	-170.00K	2.70M
Net Income	5.67M	-	-215.56M	-186.26M	-57.44M	9.66M
Diluted EPS	-	-	-0.61	-0.51	-0.15	0.02

Compounded Sales Growth

5 Years:	18.33%
1 Year:	21.20%

Compounded Profit Growth

5 Years:	34.83%
1 Year:	1,927.50%

Stock Price Performance

1 Year:	+29.80%
6 Months:	+16.29%
3 Months:	+6.49%
1 Month:	+3.77%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Apr 2020	May 2020	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	1.57B	-	2.17B	2.11B	2.12B	2.20B
Current Assets	-	-	-	-	-	-	233.22M	225.73M	312.51M	416.20M
Cash & Equivalents	-	-	-	-	18.83M	-	108.62M	78.82M	154.57M	248.64M
Inventory	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	100.87M	125.41M	131.80M	95.71M
Total Liabilities	-	-	-	-	536.89M	-	655.15M	681.04M	672.01M	682.92M
Current Liabilities	-	-	-	-	75.92M	-	176.00M	202.87M	228.89M	251.96M
Long Term Debt	-	-	-	-	362.53M	-	225.08M	280.29M	279.79M	265.93M
Total Debt	-	-	-	-	-	-	476.49M	511.04M	485.19M	474.52M
Total Equity	-109.10M	-166.35M	0	-464.38M	997.84M	-	1.52B	1.43B	1.45B	1.52B
Shares Outstanding	-	-	-	-	-	-	375.96M	378.73M	382.74M	388.32M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2019	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	17.05M	-	52.79M	-16.88M	107.26M	146.15M
Investing Cash Flow	-73.38M	-	-139.46M	-60.34M	-21.57M	-36.12M
Financing Cash Flow	48.46M	-	47.26M	47.43M	-9.95M	-15.96M
Capital Expenditure	-14.31M	-	-79.25M	-40.52M	-21.57M	-36.12M
Free Cash Flow	2.73M	-	-26.47M	-57.40M	85.69M	110.03M
Net Change in Cash	-	-	-39.41M	-29.80M	75.75M	94.07M

Ratios (Annual)

Figures in %.

Metric	Dec 2019	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	27.6%	28.6%	32.2%	32.4%
Operating Margin %	-	-	-24.5%	-17.9%	-2.5%	1.7%
Net Margin %	-	-	-25.1%	-17.6%	-4.6%	0.7%
ROE %	-3.4%	-	-14.2%	-13.0%	-4.0%	0.6%
ROCE %	-	-	-10.5%	-9.9%	-1.7%	1.2%

Shareholding Pattern

Insiders

4.59%

Institutions

88.56%

Public Float

92.82%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	TPG GP A, LLC	36.10%	140.03M	$1.08B
2	FMR, LLC	15.13%	58.69M	$452.47M
3	Summit Partners, L.P.	7.53%	29.21M	$225.21M
4	Blackrock Inc.	4.68%	18.13M	$139.82M
5	Dimensional Fund Advisors LP	2.67%	10.37M	$79.93M
6	Jennison Associates LLC	2.64%	10.23M	$78.86M
7	Vanguard Portfolio Management LLC	2.50%	9.68M	$74.65M
8	Vanguard Capital Management LLC	2.04%	7.91M	$60.97M
9	Silversmith Partners I GP, LLC	1.59%	6.16M	$47.47M
10	UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	1.57%	6.09M	$46.97M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LFST

No recent headlines available.

LFST · Healthcare